أسـهم تـحت المـجـهر uthr

[aburakan]

من الشركات الطبية

- تنتج الشركة منتج اسمه (اليمودلين) الذى يستخدم عافانا الله لعلاج مرض ارتفاع ضغط الدم الشريانى الرئوي.

- آخر أخبارها وافضلها على الاطلاق خبر نزل امس قبل الاغلاق بنصف ساعه وهو اعتماد منتجهم :-

United Thera: FDA Approves Intravenous Dosing of Remodulin for the Treatment of Pulmonary Arterial Hypertension (UTHR) 38.26 +2.93: Co announced

- السهم كسر الهاى السنوي القديم
38.04 $

- بعد الخبر طيران من
38.26 $ الى 44.38 $

- حجم التداول تجاوز العشر اضعاف الافرج فوليوم ل3 أشهر
avg vol

565 ألف

vol

5.9 مليون

- الأسهم المصدرة
22.30 m

-الأسهم المتداولة (الفلوت)
21.10 m


شارت السكستي

 

[aburakan]

شارت الديلى والاختراق الواضح

 

[aburakan]

الويكلى ويوضح الدعم القوي من متوسط الخمسين لحركة السهم

 

[aburakan]

اب قريد ورفع التارقت من 36 $ اللى 60 $ !!!

طيران

UTHR United Thera target increased to $60 at Rodman & Renshaw; Wachovia says Remodulin approval is best-case outcome (41.54 )

Rodman & Renshaw raises their tgt on UTHR to $60 from $36 after the co announced Remodulin approval. Firm says their previous models did not include any sales of Remodulin from IV formulation, and says that approval of IV Remodulin removes significant risk from UTHR shares and positions the co for a favorable earnings growth rate over the next few years given the high margins for Remodulin. Firm believes that at current valuations UTHR is one of the best value plays in biotech today, and remains one of their top picks for 2005... Wachovia says the approval of Remodulin is a best-case positive outcome that supports further upside in the stock. Though the new Remodulin label recommends IV Remodulin for those who cannot tolerate SC Remodulin, firm believes this will have a minimal effect, if any, on physician adoption, reimbursement, and competitive dynamics in the PAH mkt. Firm believes that upside could exist to their 2005-06 Remodulin ests of $102 mln and $142 mln, respectively, due to stronger than expected pricing and/or switching from Flolan to IV Remodulin. Firm sees valuation range of $48 to $52. Maintains Outperform.

 

[aburakan]

يوم الجمعة عمل السهم نيو يير هاى
46.44 $

اليوم يتحدد مسار السهم

تسكير قاب ام الذهاب الى نيو يير هاى جديد

للمتابعة